Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avecho BiotechnologyASX:AVE EV-to-EBIT is -20.32 as of Aug. 10, 2026. The stock has 2 warning signs investors should review. Among 370 Biotechnology companies, Avecho Biotechnology ranks worse than 270270% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Avecho Biotechnology's Enterprise Value for the quarter that ended in Dec. 2025 was A$28.41 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Avecho Biotechnology's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-3.96 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avecho Biotechnology EV-to-EBIT Related Terms
Avecho Biotechnology EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Avecho Biotechnology's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:AVE vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, Avecho Biotechnology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avecho Biotechnology EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avecho Biotechnology's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Avecho Biotechnology's EV-to-EBIT falls into.
Avecho Biotechnology's current Enterprise Value is A$80.35 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Avecho Biotechnology's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-3.96 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avecho Biotechnology (ASX:AVE) has a EV-to-EBIT of -20.32 as of Aug. 10, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Avecho Biotechnology and its competitors. According to the industry distribution chart, Avecho Biotechnology ranks #999999 out of 370 companies in the Biotechnology industry.
Is Avecho Biotechnology's EV-to-EBIT too high?
Avecho Biotechnology's current EV-to-EBIT is -20.32. Based on the distribution chart, Avecho Biotechnology ranks #999999 out of 370 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Avecho Biotechnology's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Avecho Biotechnology ranks #999999 out of 370 companies for EV-to-EBIT. This places Avecho Biotechnology in the lower half of its industry. The industry median EV-to-EBIT is 15.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.03, based on 370 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Avecho Biotechnology and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avecho Biotechnology's current EV-to-EBIT is -20.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avecho Biotechnology stock overvalued right now?
Avecho Biotechnology (ASX:AVE) has a current EV-to-EBIT of -20.32. The current EV-to-EBIT is -20.32. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Avecho Biotechnology (ASX:AVE), the current EV-to-EBIT is -20.32 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sales, and licensing of products incorporating its patented platform technology Tocopheryl Phosphate Mixture (TPM), for the pharmaceutical, skincare, and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches, including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AVE has been successfully added to your 
